4 replies to this topic

[Happycat]

Has anyone else seen this?  Apparently, there were a lot of blood clots popping up in patients. I'm not sure what this will mean for those currently taking it. Sounds like they will lower the dose. Just google it, you'll find it.

Traci

[Susan61]

Yes I know someone who has been on Ponatinib, and they did very well as far as achieving a PCRU status.  Nothing else worked for her.  Unfortunately, she developed blockages in her leg.  She just underwent extensive surgery to have veins taken from her good leg to repair the left leg.  She is doing great now, and says that she will be put on Tasigna.

She has no idea why they never tried the Tasigna before.  They have had her on everything else, and did not work for her.  I wish her the very best with the Tasigna.

Susan

[GerryL]

Ariad's Nasty Surprise Gives The Sellside Pause For Thought

The shock US FDA hold slapped today on studies of Ariad Pharmaceuticals' (ARIA) leukemia drug Iclusig serves as a timely reminder to sellside analysts of the high risk associated even with advanced projects, let alone those in early development.

http://seekingalpha....l_rt_mc_focus_0

[Trey]

Iclusig is the only T315i drug currently available, so those who have T315i need it.  Some others who fail all other drugs also need it.  Anyone else should try Tasigna and Sprycel first, and maybe Bosulif also.  It would be a last resort drug based on the trial data.  If I were on Iclusig I would look at lowering the dosage after CCyR.

[hannibellemo]

I had not seen this until you posted it, however, I had an appointment with my local onc who was talking with Dr. Letendre at Mayo last week. He said they had been seeing many issues with both Bosulif and Iclusig. My take on this is that Iclusig is still available for those with the T315i mutation and those who have not responded to G, S or T? I don't know what FDA considers an acceptable risk, but I hope Iclusig is still available for them and this article is shutting down, for now, only trials for first line patients.

Pat